Skip to main content
. 2022 Jan 18;12:783806. doi: 10.3389/fimmu.2021.783806

Figure 3.

Figure 3

Melatonin inhibits type 2 immunity in oxazolone (Oxa)-induced colitis. (A, B) Flow cytometry analysis of IL-5 and IL-13 in colonic CD45+LinGATA3+ ILC2s and quantification of IL-13 in colonic ILC2s in melatonin-treated and melatonin-untreated mice at day 1 after 3% oxazolone enema. (C, D) qPCR of Il-5 and Il-13 mRNA of colonic tissue in melatonin-treated and melatonin-untreated mice at day 1 after 3% oxazolone enema (all values were normalized to the melatonin-untreated group). (E, F) Representative flow cytometry plots and quantification of large intestinal CD45+LinGATA3+ ILC2 function treated with melatonin for 16 h in LPLs in vitro. (G, H) Representative flow cytometry plots and quantification of purified large intestinal CD45+LinCD127+KLRG1+ ILC2 function treated with melatonin for 16 h in vitro. Data are representative of at least two independent experiments. Data are shown as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.